Table 1.

Currently recruiting trials of PARPi and chemotherapy combinations

PARPi/chemo combination	Phase of study	Population
BMN673 + TMZ NCT02116777	Phase I dose escalation followed by Phase II	Phase II: patients aged >12 months and ≤21 months, relapsed/refractory solid tumors Phase I: >12 months and ≤30 months, Ewing’s sarcoma, PNET, ALL
Olaparib + C AUC4 NCT01237067	Phase I	Recurrent/refractory gynecologic tumors and recurrent/refractory metastatic BC BRCA mutation BC that is locally advanced or metastatic, even if not treated previously
AZD2281 + C NCT01445418	Phase I	BRCA +ve BC and OC Sporadic OC Sporadic TNBC
Niraparib + TMZ NCT02044120	Phase I	Previously treated, incurable Ewing’s sarcoma
Veliparib + pegylated liposomal doxorubicin NCT01145430	Phase I	Recurrent OC, fallopian tube cancer, PPC, metastatic TNBC (BRCA +ve and −ve)
Veliparib + floxuridine NCT01749397	Phase I	Metastatic epithelial ovarian, PPC, or fallopian tube cancer
Olaparib + TMZ NCT01390571	Phase I	Relapsed glioblastoma
TMZ +/− veliparib NCT01638546	Phase II, randomized placebo-controlled	Relapsed or refractory small cell lung cancer
E7449 single agent or with TMZ or with C and P NCT01618136	Phase I dose escalation followed by Phase II	Single agent: advanced solid tumors Combination arms: B cell malignancies (TMZ) or advanced solid tumors (C + P)
Veliparib + topotecan NCT01012817	Phase I dose escalation followed by Phase II	Phase I: advanced solid tumors Phase II: recurrent ovarian or PPC
Veliparib + C, P, and bevacizumab NCT00989651	Phase I	Newly diagnosed stage II, III, or IV OC, fallopian tube cancer, or PPC

Abbreviations: ALL, acute lymphoblastic leukemia; AUC, area under the curve; BC, breast cancer; C, carboplatin; OC, ovarian cancer; P, paclitaxel; PNET, peripheral primitive neuroectodermal tumor; PPC, primary peritoneal cancer; TMZ, temozolomide; TNBC, triple negative breast cancer.